This trial will test the effect of Lisdexamfetamine dimesylate on children and adolescents with ADHD and comorbid Autism Spectrum Disorder.
1 Primary · 6 Secondary · Reporting Duration: 12 weeks
40 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 4
Age 6 - 12 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:18 - 65 | 100.0% |
Center for Pediatric Excellence | 100.0% |
Met criteria | 100.0% |
3+ | 100.0% |